The naming of medicines follows international standards, with the World Health Organization (WHO) assigning International Nonproprietary Names (INNs), while the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the licensing and reviews brand names in the UK
Dyslipidaemia (odds ratio (OR) 1.6), hypertension (OR 1.5), and concurrent biologic therapy (OR 1.5) were all associated with increased likelihood of GLP-1 agonist use, highlighting the interconnected nature of metabolic and inflammatory conditions in HS management
Methionine cycle intermediate, SAMe, demonstrates antioxidant properties, influences DNA methylation, elevates GSH levels, and, at elevated doses, mitigates neuronal loss in NDs (178)
Mounjaro, as a newer entrant, offers a fresh perspective on using GLP-1 receptor agonists for weight management
Does my semaglutide cost change if my dose increases